Thrombolysis for central retinal artery occlusion: An individual participant-level meta-analysis.

Retinal artery occlusion antiplatelet therapy aspirin thrombolytic therapy tissue plasminogen activator visual acuity

Journal

International journal of stroke : official journal of the International Stroke Society
ISSN: 1747-4949
Titre abrégé: Int J Stroke
Pays: United States
ID NLM: 101274068

Informations de publication

Date de publication:
27 Jul 2023
Historique:
pubmed: 10 7 2023
medline: 10 7 2023
entrez: 10 7 2023
Statut: aheadofprint

Résumé

Whether thrombolysis improves outcomes in non-arteritic central retinal artery occlusion (naCRAO) is uncertain. We aimed to evaluate the rate of visual recovery after intra-venous thrombolysis (IVT) or intra-arterial thrombolysis (IAT) administration of tissue plasminogen activator (tPA) or urokinase among patients with naCRAO and explore the parameters affecting the final visual acuity (VA). We systematically searched six databases. Logarithm of the minimum angle of resolution (logMAR) and VA of ⩾20/100 were used to quantify visual recovery. To explore the role of other factors on visual recovery, we defined two models for studies with aggregated data (designs 1 and 2) and 16 models for individual participant data (IPD, models 1-16). We included data from 771 patients out of 72 publications in nine languages. Visual improvement for ⩾0.3 logMAR was reported in 74.3% of patients who received IVT-tPA within 4.5 h (CI: 60.9-86.0%; unadjusted rate: 73.2%) and 60.0% of those who received IAT-tPA within 24 h (CI: 49.1-70.5%; unadjusted rate: 59.6%). VA of ⩾20/100 was observed among 39.0% of patients after IVT-tPA within 4.5 h and 21.9% of those with IAT-tPA within 24 h. IPD models highlighted the association between improved visual outcomes and VA at presentation, at least 2 weeks follow-up before reporting the final VA, antiplatelet therapy, and shorter symptom onset to thrombolysis window. Early thrombolytic therapy with tPA is associated with enhanced visual recovery in naCRAO. Future studies should refine the optimum time window for thrombolysis in naCRAO.

Sections du résumé

BACKGROUND UNASSIGNED
Whether thrombolysis improves outcomes in non-arteritic central retinal artery occlusion (naCRAO) is uncertain. We aimed to evaluate the rate of visual recovery after intra-venous thrombolysis (IVT) or intra-arterial thrombolysis (IAT) administration of tissue plasminogen activator (tPA) or urokinase among patients with naCRAO and explore the parameters affecting the final visual acuity (VA).
AIM UNASSIGNED
We systematically searched six databases. Logarithm of the minimum angle of resolution (logMAR) and VA of ⩾20/100 were used to quantify visual recovery. To explore the role of other factors on visual recovery, we defined two models for studies with aggregated data (designs 1 and 2) and 16 models for individual participant data (IPD, models 1-16).
SUMMARY OF REVIEW UNASSIGNED
We included data from 771 patients out of 72 publications in nine languages. Visual improvement for ⩾0.3 logMAR was reported in 74.3% of patients who received IVT-tPA within 4.5 h (CI: 60.9-86.0%; unadjusted rate: 73.2%) and 60.0% of those who received IAT-tPA within 24 h (CI: 49.1-70.5%; unadjusted rate: 59.6%). VA of ⩾20/100 was observed among 39.0% of patients after IVT-tPA within 4.5 h and 21.9% of those with IAT-tPA within 24 h. IPD models highlighted the association between improved visual outcomes and VA at presentation, at least 2 weeks follow-up before reporting the final VA, antiplatelet therapy, and shorter symptom onset to thrombolysis window.
CONCLUSION UNASSIGNED
Early thrombolytic therapy with tPA is associated with enhanced visual recovery in naCRAO. Future studies should refine the optimum time window for thrombolysis in naCRAO.

Identifiants

pubmed: 37424312
doi: 10.1177/17474930231189352
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

17474930231189352

Auteurs

Shima Shahjouei (S)

Department of Neurology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.
Department of Neurology, Neurosurgery, and Translational Medicine, Barrow Neurological Institute, St. Joseph's Hospital, Phoenix, AZ, USA.

Reza Bavarsad Shahripour (R)

UCSD Comprehensive Stroke Center, Department of Neurosciences, University of California, San Diego, CA, USA.
Department of Neurology, Stroke Center, Loma Linda University, Loma Linda, CA, USA.

Oana M Dumitrascu (OM)

Division of Cerebrovascular Diseases, Department of Neurology, Mayo Clinic College of Medicine and Science, Scottsdale, AZ, USA.
Department of Ophthalmology, Mayo Clinic College of Medicine and Science, Scottsdale, AZ, USA.

Classifications MeSH